Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)

Anders Bruun Mathiasen; Erik Jørgensen; Abbas Ali Qayyum; Mandana Haack-Sørensen; Annette Ekblond; Jens Kastrup

doi:10.1016/j.ahj.2012.05.026

Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)

Anders Bruun Mathiasen, Erik Jørgensen, Abbas Ali Qayyum, Mandana Haack-Sørensen, Annette Ekblond, Jens Kastrup

79 Citationer (Scopus)

Abstract

Stem cell therapy is an emerging treatment modality in cardiovascular disease. The best cell type and delivery method in different cardiovascular diseases remain to be determined.

Originalsprog	Engelsk
Tidsskrift	American Heart Journal
Vol/bind	164
Udgave nummer	3
Sider (fra-til)	285-91
Antal sider	7
ISSN	0002-8703
DOI	https://doi.org/10.1016/j.ahj.2012.05.026
Status	Udgivet - 2012

Adgang til dokumentet

10.1016/j.ahj.2012.05.026

Fingeraftryk

Dyk ned i forskningsemnerne om 'Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Mathiasen, A. B., Jørgensen, E., Qayyum, A. A., Haack-Sørensen, M., Ekblond, A., & Kastrup, J. (2012). Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial). American Heart Journal, 164(3), 285-91. https://doi.org/10.1016/j.ahj.2012.05.026

Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial). / Mathiasen, Anders Bruun ; Jørgensen, Erik; Qayyum, Abbas Ali et al.
I: American Heart Journal, Bind 164, Nr. 3, 2012, s. 285-91.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Mathiasen, AB , Jørgensen, E, Qayyum, AA, Haack-Sørensen, M, Ekblond, A & Kastrup, J 2012, 'Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)', American Heart Journal, bind 164, nr. 3, s. 285-91. https://doi.org/10.1016/j.ahj.2012.05.026

Mathiasen AB , Jørgensen E, Qayyum AA, Haack-Sørensen M, Ekblond A, Kastrup J. Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial). American Heart Journal. 2012;164(3):285-91. doi: 10.1016/j.ahj.2012.05.026

@article{646a57d7fb654748aeb71c50b16340fa,

title = "Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)",

abstract = "Stem cell therapy is an emerging treatment modality in cardiovascular disease. The best cell type and delivery method in different cardiovascular diseases remain to be determined.",

keywords = "Bone Marrow Cells, Coronary Artery Disease, Double-Blind Method, Follow-Up Studies, Heart Failure, Humans, Injections, Magnetic Resonance Imaging, Mesenchymal Stem Cell Transplantation, Research Design, Stroke Volume, Systole, Tomography, X-Ray Computed, Transplantation, Autologous, Treatment Outcome, Ventricular Function, Left",

author = "Mathiasen, {Anders Bruun} and Erik J{\o}rgensen and Qayyum, {Abbas Ali} and Mandana Haack-S{\o}rensen and Annette Ekblond and Jens Kastrup",

year = "2012",

doi = "10.1016/j.ahj.2012.05.026",

language = "English",

volume = "164",

pages = "285--91",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)

AU - Mathiasen, Anders Bruun

AU - Jørgensen, Erik

AU - Qayyum, Abbas Ali

AU - Haack-Sørensen, Mandana

AU - Ekblond, Annette

AU - Kastrup, Jens

PY - 2012

Y1 - 2012

N2 - Stem cell therapy is an emerging treatment modality in cardiovascular disease. The best cell type and delivery method in different cardiovascular diseases remain to be determined.

AB - Stem cell therapy is an emerging treatment modality in cardiovascular disease. The best cell type and delivery method in different cardiovascular diseases remain to be determined.

KW - Bone Marrow Cells

KW - Coronary Artery Disease

KW - Double-Blind Method

KW - Follow-Up Studies

KW - Heart Failure

KW - Humans

KW - Injections

KW - Magnetic Resonance Imaging

KW - Mesenchymal Stem Cell Transplantation

KW - Research Design

KW - Stroke Volume

KW - Systole

KW - Tomography, X-Ray Computed

KW - Transplantation, Autologous

KW - Treatment Outcome

KW - Ventricular Function, Left

U2 - 10.1016/j.ahj.2012.05.026

DO - 10.1016/j.ahj.2012.05.026

M3 - Journal article

C2 - 22980293

SN - 0002-8703

VL - 164

SP - 285

EP - 291

JO - American Heart Journal

JF - American Heart Journal

IS - 3

ER -